Verici Dx PLC Ordinary Shares VRCI
Trading Information
- Previous Close Price
- GBX0.21
- Day Range
- GBX0.19–0.25
- 52-Week Range
- GBX0.19–0.99
- Bid/Ask
- GBX0.00 / GBX0.00
- Shares Outstanding
- 2.29B
- Market Cap
- GBX514.65M
- Volume/Avg
- 4M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.24
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Verici Dx PLC is the development of prognostic and diagnostic tests for kidney transplant patients. It is a commercial stage diagnostics company, transforming the outcomes of kidney transplants through a complementary suite of proprietary, edge tests. These form a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. It has developed a suite of blood-based tests for kidney transplant patients. The group has one division being the development of prognostic and diagnostic tests for kidney transplant patients. The company's products are Tutivia, Clarava, Protega. The company's services are Next Generation Sequencing Services, Bioinformatics and Data Science Services.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 22
- Website
- https://www.vericidx.com
Valuation
|
Metric
|
VRCI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.87 |
Price/Sales | 1.24 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VRCI
|
|---|---|
Quick Ratio | 2.53 |
Current Ratio | 2.82 |
Interest Coverage | −254.19 |
Quick Ratio
VRCI
Profitability
|
Metric
|
VRCI
|
|---|---|
Return on Assets (Normalized) | −111.77% |
Return on Equity (Normalized) | −2,446.05% |
Return on Invested Capital (Normalized) | −144.83% |
Return on Assets
VRCI
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|V&b^Vpdf | LOCK|L@q | $242B | |||
| Danaher Corp
DHR
| LOCK|pws%!fZ | LOCK|wSC | $150B | |||
| Agilent Technologies Inc
A
| LOCK|sQ&HKNK< | LOCK|?% | $47B | |||
| IQVIA Holdings Inc
IQV
| LOCK|K&tj?YS | LOCK|l@^b | $43B | |||
| Waters Corp
WAT
| LOCK|$p>#P& | LOCK|!<X | $42B | |||
| Illumina Inc
ILMN
| LOCK|#zZhyn> | LOCK|rPv<> | $41B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|lL%V$l%L | LOCK|b$ | $41B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|ndr^$<LX | LOCK|l%sCK | $30B | |||
| Quest Diagnostics Inc
DGX
| LOCK|ZvXbs@ | LOCK|hs&Bl | $26B | |||
| Labcorp Holdings Inc
LH
| LOCK|#sTF>BvR | LOCK|s@^?t | $25B |
United States